Trial
NCT06022757
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Evopoint Biosciences Inc.
Collaborators
Merck Sharp & Dohme LLC
Condition
Carcinoma
Intervention
XNW5004
Why stopped
Strategic decision by Sponsor.
Provenance
Dataset: 2026-07-24 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-23